journal article·2023-05Open access

SOX17 is a Critical Factor in Maintaining Endothelial Function in Pulmonary Hypertension by an Exosome‐Mediated Autocrine Manner

Xiaozhou Zou, Ting Liu, Zhongjie Huang, Wei Zhou, Mengnan Yuan, Hongying Zhao, Zongfu Pan, Pengcheng Chen, Yanfei Shao, Xiaoping Hu, Su Zhang, Shuilian Zheng, Yiwen Zhang, Ping Huang

Advanced Science· Volume 10· Issue 14

Abstract

Abstract Endothelial dysfunction is considered a predominant driver for pulmonary vascular remodeling in pulmonary hypertension (PH). SOX17, a key regulator of vascular homoeostasis, has been found to harbor mutations in PH patients, which are associated with PH susceptibility. Here, this study explores whether SOX17 mediates the autocrine activity of pulmonary artery ECs to maintain endothelial function and vascular homeostasis in PH and its underlying mechanism. It is found that SOX17 expression is downregulated in the endothelium of remodeled pulmonary arteries in IPH patients and SU5416/hypoxia (Su/hypo)‐induced PH mice as well as dysfunctional HPAECs. Endothelial knockdown of SOX17 accelerates the progression of Su/hypo‐induced PH in mice. SOX17 overexpression in the pulmonary endothelium of mice attenuates Su/hypo‐induced PH. SOX17‐associated exosomes block the proliferation, apoptosis, and inflammation of HPAECs, preventing pulmonary arterial remodeling and Su/hypo‐induced PH. Mechanistic analyses demonstrates that overexpressing SOX17 promotes the exosome‐mediated release of miR‐224‐5p and miR‐361‐3p, which are internalized by injured HPAECs in an autocrine manner, ultimately repressing the upregulation of NR4A3 and PCSK9 genes and improving endothelial function. These results suggest that SOX17 is a key gene in maintaining endothelial function and vascular homeostasis in PH through regulating exosomal miRNAs in an autocrine manner.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Pulmonary Hypertension Research and Treatments · Extracellular vesicles in disease · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Clinical Pharmacy Cancer Center Department of Pharmacy Zhejiang Provincial People's Hospital Affiliated People's Hospital Hangzhou Medical College Hangzhou 310014 P. R. China

Key Laboratory of Endocrine Gland Diseases of Zhejiang Province Hangzhou 310014 P. R. China

Department of Pharmacy Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine Hangzhou 310006 P. R. China

Department of Clinical Pharmacy Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine Hangzhou 310006 P. R. China

School of Pharmaceutical Sciences Zhejiang Chinese Medical University Hangzhou 310014 P. R. China

Zhongnan Hospital of Wuhan University Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan University Hubei Key Laboratory of Medical Technology on Transplantation Wuhan 430000 P. R. China

Funding

National Natural Science Foundation of China · Chinese Medicine Research Program of Zhejiang Province

References (70)

Show source-provided references
1. 10.1016/j.jacc.2009.04.00910.1016/j.jacc.2009.04.009 ↗
2. 10.1016/j.jacc.2009.04.01810.1016/j.jacc.2009.04.018 ↗
3. 10.1183/13993003.03957-202010.1183/13993003.03957-2020 ↗
4. 10.1016/j.bioactmat.2021.08.02910.1016/j.bioactmat.2021.08.029 ↗
5. 10.1161/CIRCRESAHA.115.30680610.1161/CIRCRESAHA.115.306806 ↗
6. 10.1038/ncb244110.1038/ncb2441 ↗
7. 10.1016/j.ymthe.2017.03.03110.1016/j.ymthe.2017.03.031 ↗
8. 10.1016/j.cell.2007.06.01110.1016/j.cell.2007.06.011 ↗
9. 10.1161/CIRCRESAHA.115.30314210.1161/CIRCRESAHA.115.303142 ↗
10. 10.1016/j.ydbio.2013.11.01810.1016/j.ydbio.2013.11.018 ↗
11. 10.1038/s41467-019-10134-y10.1038/s41467-019-10134-y ↗
12. 10.1038/s41569-019-0242-x10.1038/s41569-019-0242-x ↗
13. 10.1165/rcmb.2019-0164OC10.1165/rcmb.2019-0164OC ↗
14. 10.1038/s41467-018-03672-410.1038/s41467-018-03672-4 ↗
15. 10.1536/ihj.20-71110.1536/ihj.20-711 ↗
16. 10.1161/CIRCRESAHA.116.30598710.1161/CIRCRESAHA.116.305987 ↗
17. 10.1038/nature2136510.1038/nature21365 ↗
18. 10.1186/s12943-017-0718-410.1186/s12943-017-0718-4 ↗
19. 10.1186/1471-2164-13-35710.1186/1471-2164-13-357 ↗
20. 10.1513/AnnalsATS.201509-620AS10.1513/AnnalsATS.201509-620AS ↗
21. 10.1007/s10741-019-09802-410.1007/s10741-019-09802-4 ↗
22. 10.3390/ijms2208385210.3390/ijms22083852 ↗
23. 10.1186/s11658-020-00237-610.1186/s11658-020-00237-6 ↗
24. 10.1183/13993003.02334-202110.1183/13993003.02334-2021 ↗
25. 10.1074/jbc.M60343620010.1074/jbc.M603436200 ↗
26. 10.3389/fcell.2021.58977010.3389/fcell.2021.589770 ↗
27. 10.1093/cvr/cvz31310.1093/cvr/cvz313 ↗
28. 10.1161/CIRCRESAHA.121.31826610.1161/CIRCRESAHA.121.318266 ↗
29. 10.1111/jcmm.1677110.1111/jcmm.16771 ↗
30. 10.2741/289510.2741/2895 ↗
31. 10.1016/j.omtn.2020.10.04210.1016/j.omtn.2020.10.042 ↗
32. 10.1161/CIRCULATIONAHA.114.00912410.1161/CIRCULATIONAHA.114.009124 ↗
33. 10.1016/j.vph.2008.06.00310.1016/j.vph.2008.06.003 ↗
34. 10.1007/s10456-005-5208-410.1007/s10456-005-5208-4 ↗
35. Liu X. · Oxid. Med. Cell. Longevity · 2021 · 2021 · 1
36. 10.1161/CIRCRESAHA.117.30968110.1161/CIRCRESAHA.117.309681 ↗
37. 10.1126/science.aau697710.1126/science.aau6977 ↗
38. 10.1161/CIRCULATIONAHA.112.11417310.1161/CIRCULATIONAHA.112.114173 ↗
39. 10.1016/j.drudis.2018.12.00110.1016/j.drudis.2018.12.001 ↗
40. 10.1093/emboj/19.19.517810.1093/emboj/19.19.5178 ↗
41. 10.1038/srep2151810.1038/srep21518 ↗
42. 10.1083/jcb.20090104010.1083/jcb.200901040 ↗
43. 10.18632/oncotarget.1258210.18632/oncotarget.12582 ↗
44. 10.2147/OTT.S22053610.2147/OTT.S220536 ↗
45. 10.1038/ncomms360910.1038/ncomms3609 ↗
46. 10.1161/ATVBAHA.113.30206210.1161/ATVBAHA.113.302062 ↗
47. 10.1042/CS2019083510.1042/CS20190835 ↗
48. 10.1002/1878-0261.1258810.1002/1878-0261.12588 ↗
49. 10.3389/fonc.2020.0052610.3389/fonc.2020.00526 ↗
50. 10.1161/HYPERTENSIONAHA.117.1009410.1161/HYPERTENSIONAHA.117.10094 ↗
51. 10.1038/s41467-019-09530-110.1038/s41467-019-09530-1 ↗
52. 10.1111/jcmm.1494010.1111/jcmm.14940 ↗
53. 10.1002/jcb.2897510.1002/jcb.28975 ↗
54. 10.7150/ijms.1956510.7150/ijms.19565 ↗
55. 10.1002/jcb.2850710.1002/jcb.28507 ↗
56. 10.1155/2019/475906010.1155/2019/4759060 ↗
57. 10.1016/j.tcm.2007.02.00110.1016/j.tcm.2007.02.001 ↗
58. 10.1161/01.CIR.0000028811.03056.BF10.1161/01.CIR.0000028811.03056.BF ↗
59. 10.1161/01.RES.0000050921.53008.4710.1161/01.RES.0000050921.53008.47 ↗
60. 10.1111/j.1538-7836.2007.02627.x10.1111/j.1538-7836.2007.02627.x ↗
61. Huang K. · Int. J. Clin. Exp. Pathol. · 2020 · 13 · 1243
62. 10.3389/fimmu.2018.0262110.3389/fimmu.2018.02621 ↗
63. 10.1038/ncomms1407910.1038/ncomms14079 ↗
64. 10.1002/path.463010.1002/path.4630 ↗
65. 10.1152/ajpheart.00169.201210.1152/ajpheart.00169.2012 ↗
66. 10.1016/j.ejphar.2017.10.03710.1016/j.ejphar.2017.10.037 ↗
67. 10.1016/j.jacc.2016.09.94510.1016/j.jacc.2016.09.945 ↗
68. 10.1038/srep2004610.1038/srep20046 ↗
69. 10.1186/s12967-016-0893-x10.1186/s12967-016-0893-x ↗
70. 10.1038/ncomms398010.1038/ncomms3980 ↗